Abstract
The epidermal growth factor receptor (EGFR) is a transmembrane tyrosine kinase receptor that is frequently overexpressed in several epithelial tumors. The EGFR was among the first cell membrane growth factor receptor to be proposed for cancer therapy and two EGFR targeted pharmacologic approaches have been successfully developed: monoclonal antibodies (MAbs) and small molecule inhibitors of the EGFR tyrosine kinase enzymatic activity (TKIs). These approaches have been tested in several human cancers, such as non small cell lung cancer (NSCLC), colorectal cancer (CRC), head and neck cancer and pancreatic cancer. However, only a subset of cancer patients will eventually benefit for the treatment with EGFR inhibitors. Therefore, the identification and the clinical validation of criteria for identifying patients which could more likely have a therapeutic advantage from the treatment with these drugs is a urgent clinical need. In the past few years, a series of reports have suggested that certain clinico-pathologic characteristics as well as specific gene alterations of the EGFR and of other genes such as K-RAS could help to identify patients whose cancers could be either sensitive or resistant to EGFR inhibitor therapy. Here we review the available clinical data which could help in defining a strategy to select patients for a more effective therapeutic use of anti-EGFR drugs.
Keywords: EGFR, erlotinib, gefitinib, cetuximab, panitumumab
Current Signal Transduction Therapy
Title: Clinico-Pathologic and Biologic Predictors of EGFR Inhibitors Activity and Efficacy in Lung and in Colorectal Cancer
Volume: 3 Issue: 3
Author(s): Maria Anna Bareschino, Clorinda Schettino, Linda Alvino, Cesare Gridelli and Fortunato Ciardiello
Affiliation:
Keywords: EGFR, erlotinib, gefitinib, cetuximab, panitumumab
Abstract: The epidermal growth factor receptor (EGFR) is a transmembrane tyrosine kinase receptor that is frequently overexpressed in several epithelial tumors. The EGFR was among the first cell membrane growth factor receptor to be proposed for cancer therapy and two EGFR targeted pharmacologic approaches have been successfully developed: monoclonal antibodies (MAbs) and small molecule inhibitors of the EGFR tyrosine kinase enzymatic activity (TKIs). These approaches have been tested in several human cancers, such as non small cell lung cancer (NSCLC), colorectal cancer (CRC), head and neck cancer and pancreatic cancer. However, only a subset of cancer patients will eventually benefit for the treatment with EGFR inhibitors. Therefore, the identification and the clinical validation of criteria for identifying patients which could more likely have a therapeutic advantage from the treatment with these drugs is a urgent clinical need. In the past few years, a series of reports have suggested that certain clinico-pathologic characteristics as well as specific gene alterations of the EGFR and of other genes such as K-RAS could help to identify patients whose cancers could be either sensitive or resistant to EGFR inhibitor therapy. Here we review the available clinical data which could help in defining a strategy to select patients for a more effective therapeutic use of anti-EGFR drugs.
Export Options
About this article
Cite this article as:
Bareschino Anna Maria, Schettino Clorinda, Alvino Linda, Gridelli Cesare and Ciardiello Fortunato, Clinico-Pathologic and Biologic Predictors of EGFR Inhibitors Activity and Efficacy in Lung and in Colorectal Cancer, Current Signal Transduction Therapy 2008; 3 (3) . https://dx.doi.org/10.2174/157436208785699668
DOI https://dx.doi.org/10.2174/157436208785699668 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Structure-Based Drug Design of Novel MARK-3 Inhibitors in Cancer
Current Bioactive Compounds Molecular Targeted Therapy in Melanoma: A Way to Reverse Resistance to Conventional Drugs
Current Drug Delivery Patents on Immunotoxins and Chimeric Toxins for the Treatment of Cancer
Recent Patents on Drug Delivery & Formulation The Novel Synthesized Pyridazinone Derivates had the Antiproliferative and Apoptotic Effects in SHSY5Y and HEP3B Cancer Cell Line
Letters in Organic Chemistry The Hepatocyte Growth Factor Receptor: Structure, Function and Pharmacological Targeting in Cancer
Current Signal Transduction Therapy Molecular Imaging of Therapeutic Potential of Reporter Probes
Current Drug Targets Iterative Image Reconstruction Algorithms for CT Metal Artifact Reduction: A Review
Recent Patents on Medical Imaging Procathepsin D as a Tumor Marker, Anti-Cancer Drug or Screening Agent
Anti-Cancer Agents in Medicinal Chemistry Mechanisms and Treatment of Neuropathic Pain
Central Nervous System Agents in Medicinal Chemistry Melatonin as a Pleiotropic Molecule with Therapeutic Potential for Type 2 Diabetes and Cancer
Current Medicinal Chemistry Acute Hypersensitivity Reactions to Chemotherapy Agents: An Overview
Inflammation & Allergy - Drug Targets (Discontinued) Monoclonal Antibodies as Cancer Therapeutics
Recent Patents on Biotechnology Novel Oral Anticoagulants: Recommendations for Patient Evaluation, Treatment Initiation, Follow-up and Perioperative Management
Cardiovascular & Hematological Disorders-Drug Targets Monoclonal Antobodies: Application in Radiopharmacy
Current Radiopharmaceuticals Recent Developments in the Field of Tumor-Inhibiting Metal Complexes
Current Pharmaceutical Design Scaffold Vascularization: A Challenge for Three-Dimensional Tissue Engineering
Current Medicinal Chemistry The Renin-angiotensin System as a Target of Novel Anticancer Therapy
Current Pharmaceutical Design Therapeutic Potential of Natural Compounds that Regulate the Activity of Protein Kinase C
Current Medicinal Chemistry Cancer-Type Organic Anion Transporting Polypeptide 1B3: Current Knowledge of the Gene Structure, Expression Profile, Functional Implications and Future Perspectives
Current Drug Metabolism Potential Roles of Eosinophils in Cancer Therapy: Epidemiological Studies, Experimental Models, and Clinical Pathology
Recent Patents on Anti-Cancer Drug Discovery